BMS-986012 + carboplatin + etoposide + nivolumab

BMS-986012 + carboplatin + etoposide + nivolumab is a drug combination under investigation for the treatment of **extensive-stage small cell lung cancer (ES-SCLC)**. - **BMS-986012** is a nonfucosylated, fully human IgG1 monoclonal antibody that targets **fucosyl-GM1**, a ganglioside highly expressed on SCLC cells but limited in normal tissue. Its mechanism includes inducing tumor cell death via antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. - **Carboplatin** and **etoposide** are standard cytotoxic chemotherapies that inhibit DNA synthesis and induce apoptosis in cancer cells. - **Nivolumab** is a monoclonal antibody immune checkpoint inhibitor targeting **programmed cell death protein 1 (PD-1)**, blocking immune suppression and enhancing anti-tumor activity. This combination aims to synergistically target cancer cells through direct cytotoxicity, immune-mediated cell death, and checkpoint blockade, potentially improving response rates and survival.